Advertisement
RGEN vs WST
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Hold and WST is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RGEN’s FA Score shows that 0 FA rating(s) are green whileWST’s FA Score has 0 green FA rating(s).
- RGEN’s FA Score: 0 green, 5 red.
- WST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RGEN’s TA Score shows that 4 TA indicator(s) are bullish while WST’s TA Score has 4 bullish TA indicator(s).
- RGEN’s TA Score: 4 bullish, 5 bearish.
- WST’s TA Score: 4 bullish, 6 bearish.
Price Growth
RGEN (@Pharmaceuticals: Other) experienced а -1.86% price change this week, while WST (@Pharmaceuticals: Other) price change was -5.82% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.03%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +8.18%.
Reported Earning Dates
RGEN is expected to report earnings on Feb 25, 2026.
WST is expected to report earnings on Feb 12, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| RGEN | WST | RGEN / WST | |
| Capitalization | 8.73B | 18.6B | 47% |
| EBITDA | 99.5M | 769M | 13% |
| Gain YTD | 7.732 | -21.011 | -37% |
| P/E Ratio | 7753.50 | 38.21 | 20,293% |
| Revenue | 674M | 3.02B | 22% |
| Total Cash | 709M | 446M | 159% |
| Total Debt | 686M | 298M | 230% |
RGEN | WST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 50 | |
PRICE GROWTH RATING 1..100 | 46 | 53 | |
P/E GROWTH RATING 1..100 | 43 | 61 | |
SEASONALITY SCORE 1..100 | 50 | 44 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WST's Valuation (86) in the Medical Specialties industry is in the same range as RGEN (97) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.
WST's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.
WST's SMR Rating (50) in the Medical Specialties industry is somewhat better than the same rating for RGEN (87) in the Biotechnology industry. This means that WST’s stock grew somewhat faster than RGEN’s over the last 12 months.
RGEN's Price Growth Rating (46) in the Biotechnology industry is in the same range as WST (53) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to WST’s over the last 12 months.
RGEN's P/E Growth Rating (43) in the Biotechnology industry is in the same range as WST (61) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to WST’s over the last 12 months.
| RGEN | WST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 1 day ago 43% |
| Stochastic ODDS (%) | 2 days ago 79% | 1 day ago 68% |
| Momentum ODDS (%) | 2 days ago 71% | 1 day ago 65% |
| MACD ODDS (%) | 2 days ago 87% | 1 day ago 64% |
| TrendWeek ODDS (%) | 2 days ago 78% | 1 day ago 60% |
| TrendMonth ODDS (%) | 2 days ago 71% | 1 day ago 62% |
| Advances ODDS (%) | 8 days ago 75% | 9 days ago 68% |
| Declines ODDS (%) | 13 days ago 81% | 1 day ago 57% |
| BollingerBands ODDS (%) | 2 days ago 90% | 1 day ago 66% |
| Aroon ODDS (%) | 2 days ago 81% | 1 day ago 70% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| FOREX / NAME | Price $ | Chg $ | Chg % |
| USDCHF | 0.80 | N/A | N/A |
| United States Dollar - Switzerland Franc | |||
| EURCHF | 0.93 | N/A | N/A |
| Euro - Switzerland Franc | |||
| HKDCHF | 0.10 | N/A | N/A |
| Hong Kong Dollar - Switzerland Franc | |||
| MSOIX | 36.99 | -0.08 | -0.22% |
| NYLI WMC Enduring Capital Class I | |||
| NQGCX | 40.67 | -0.27 | -0.66% |
| Nuveen Global Equity Income C | |||